Next Article in Journal
An Overview of Influenza Viruses and Vaccines
Previous Article in Journal
Immunological Analysis of People in Northeast China after SARS-CoV-2 Inactivated Vaccine Injection
Article

Prospective Cohort Study of the Kinetics of Specific Antibodies to SARS-CoV-2 Infection and to Four SARS-CoV-2 Vaccines Available in Serbia, and Vaccine Effectiveness: A 3-Month Interim Report

1
Department of Microbiology and Parasitology, Institute for Medical Research, University of Belgrade, 11129 Belgrade, Serbia
2
Faculty of Information Technology, Alfa BK University, 11070 Belgrade, Serbia
3
Zentrix Lab, 26000 Pančevo, Serbia
*
Author to whom correspondence should be addressed.
Academic Editor: Siddappa N. Byrareddy
Vaccines 2021, 9(9), 1031; https://doi.org/10.3390/vaccines9091031
Received: 10 August 2021 / Revised: 8 September 2021 / Accepted: 13 September 2021 / Published: 17 September 2021
(This article belongs to the Section COVID-19 Vaccines and Vaccination)
Real-life data on the performance of vaccines against SARS-CoV-2 are still limited. We here present the rates of detection and levels of antibodies specific for the SARS-CoV-2 spike protein RBD (receptor binding domain) elicited by four vaccines available in Serbia, including BNT-162b2 (BioNTech/Pfizer), BBIBP-CorV (Sinopharm), Gam-COVID-Vac (Gamaleya Research Institute) and ChAdOx1-S (AstraZeneca), compared with those after documented COVID-19, at 6 weeks and 3 months post first vaccine dose or post-infection. Six weeks post first vaccine dose, specific IgG antibodies were detected in 100% of individuals fully vaccinated with BNT-162b2 (n = 100) and Gam-COVID-Vac (n = 12) and in 81.7% of BBIBP-CorV recipients (n = 148), while one dose of ChAdOx1-S (n = 24) induced specific antibodies in 75%. Antibody levels elicited by BNT-162b2 were higher, while those elicited by BBIBP-CorV were lower, than after SARS-CoV-2 infection. By 3 months post-vaccination, antibody levels decreased but remained ≥20-fold above the cut-off in BNT-162b2 but not in BBIBP-CorV recipients, when an additional 30% were seronegative. For all vaccines, antibody levels were higher in individuals with past COVID-19 than in naïve individuals. A total of twelve new infections occurred within the first 3 months post-vaccination, eight after the first dose of BNT-162b2 and ChAdOx1-S (one each) and BBIBP-CorV (six), and four after full vaccination with BBIBP-CorV, but none required hospitalization. View Full-Text
Keywords: SARS-CoV-2; COVID-19; BNT-162b2; BBIBP-CorV; Gam-COVID-Vac; ChAdOx1-S; specific antibodies; vaccine effectiveness SARS-CoV-2; COVID-19; BNT-162b2; BBIBP-CorV; Gam-COVID-Vac; ChAdOx1-S; specific antibodies; vaccine effectiveness
Show Figures

Figure 1

MDPI and ACS Style

Lijeskić, O.; Klun, I.; Stamenov Djaković, M.; Gligorić, N.; Štajner, T.; Srbljanović, J.; Djurković-Djaković, O. Prospective Cohort Study of the Kinetics of Specific Antibodies to SARS-CoV-2 Infection and to Four SARS-CoV-2 Vaccines Available in Serbia, and Vaccine Effectiveness: A 3-Month Interim Report. Vaccines 2021, 9, 1031. https://doi.org/10.3390/vaccines9091031

AMA Style

Lijeskić O, Klun I, Stamenov Djaković M, Gligorić N, Štajner T, Srbljanović J, Djurković-Djaković O. Prospective Cohort Study of the Kinetics of Specific Antibodies to SARS-CoV-2 Infection and to Four SARS-CoV-2 Vaccines Available in Serbia, and Vaccine Effectiveness: A 3-Month Interim Report. Vaccines. 2021; 9(9):1031. https://doi.org/10.3390/vaccines9091031

Chicago/Turabian Style

Lijeskić, Olivera, Ivana Klun, Marija Stamenov Djaković, Nenad Gligorić, Tijana Štajner, Jelena Srbljanović, and Olgica Djurković-Djaković. 2021. "Prospective Cohort Study of the Kinetics of Specific Antibodies to SARS-CoV-2 Infection and to Four SARS-CoV-2 Vaccines Available in Serbia, and Vaccine Effectiveness: A 3-Month Interim Report" Vaccines 9, no. 9: 1031. https://doi.org/10.3390/vaccines9091031

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop